# [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)

> **NCT02621606** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** [11C]MK-6884

## Key facts

- **NCT ID:** NCT02621606
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-08
- **Primary completion:** 2017-12-28
- **Final completion:** 2017-12-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02621606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02621606, "[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02621606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*